The ORCA (Observer-Reported Communication Ability) outcome measure

In 2018, FAST funded Dr. Bryce Reeve of Duke University to create a novel communication measurement tool as an outcome measure assessment of caregiver observations of a child’s ability for expressive communication in nonverbal patients with complex communication needs like Angelman syndrome (AS).  We are happy to announce that not only was Dr. Reeve successful […]

FAST Awards Drs. Silverman (UC-Davis) and Duis (Children’s Hospital Colorado) Grant to Study Gait as an Outcome Measure for Angelman Syndrome

Movement disorders affect nearly all individuals with Angelman syndrome (AS), with the most common concerns being spasticity, ataxia (as observed in the majority of ambulatory individuals), tremor, and muscle weakness. Clinically, over time, individuals may develop a crouched gait which can cause a progressive decline in mobility.  Similar motor disorders are observed in Angelman syndrome rodent […]

FAST Conference Draws 20 Pharmaceutical Companies and Raises Over $2.2 Million for Research

Downers Grove, IL – December 7, 2020 – The Foundation for Angelman Syndrome Therapeutics (FAST) today announced that Virtually Unstoppable, their annual Summit & Gala benefitting Angelman syndrome (AS) raised over $2.2 million during their virtual two-day conference. The conference included two science conferences, an educational and best practices workshop, and a mini-Gala featuring award […]

The Next Frontier in FAST Funded Research

For 12 years FAST has been working diligently to fundraise, identify research opportunities, and wisely invest in science in order to develop real and effective treatments for our loved ones living with Angelman syndrome (AS). Thanks to your fundraising dollars, FAST has funded important pre-clinical work, developed much-needed outcome measures, and played an integral role […]

FAST Funds Dr. Albert J. Keung’s Creation of Cell Lines and Organoids of Class I Deleted Genes

The past decade has seen the development of exciting therapeutic candidates ranging from antisense oligonucleotides (ASOs) to gene replacement therapies, both aimed at replacing the UBE3A protein that is missing in the neurons of individuals living with Angelman syndrome (AS). However, approximately 70% of individuals with Angelman syndrome also have diminished levels of six to […]

FAST Awards Drs. Silverman (UC-Davis) and Duis (Children’s Hospital Colorado) Grant to Study Gait as an Outcome Measure for Angelman Syndrome

Movement disorders affect nearly all individuals with Angelman syndrome (AS), with the most common concerns being spasticity, ataxia (as observed in the majority of ambulatory individuals), tremor, and muscle weakness. Clinically, over time, individuals may develop a crouched gait which can cause a progressive decline in mobility.  Similar motor disorders are observed in Angelman syndrome rodent […]

FAST Grant to Dr. Scott Dindot for Translational Research in a Pig Model of Angelman Syndrome

Like humans with Angelman syndrome (AS), mouse models of AS exhibit seizures, impaired cognition, abnormal sleep, and motor-defects; however, the expressivity and penetrance of these phenotypes are strain- and age-dependent and largely less pronounced relative to those observed in individuals with Angelman syndrome. In 2015, FAST and FAST Australia funded Dr. Scott Dindot at Texas […]

Interview with FAST UK Chairperson Tom Keogh

How was FAST UK born? “FAST (Foundation for Angelman Syndrome Therapeutics) UK was born after our eldest daughter Amelia was diagnosed with Angelman syndrome just after her first birthday. After the initial shock of the diagnosis, my wife Tam and I started looking around to see what help was available and we came across FAST.  […]

X
X